Alpha-methyl-acyl-CoA racemase deficiency, often shortened to AMACR deficiency, is a very rare inherited metabolic disease. It happens when the body cannot make enough working alpha-methyl-acyl-CoA racemase enzyme. This enzyme helps break down some special fats, especially branched-chain fatty acids and some bile acid intermediates. When the enzyme does not work well, harmful substances can build up in the body. These substances can affect the brain, nerves, eyes, and sometimes the liver. In many people, symptoms start in adulthood and slowly become worse over time.
Alpha-methyl-acyl-CoA racemase deficiency, also called AMACR deficiency or congenital bile acid synthesis defect type 4, is a very rare inherited disease. In this disease, the body cannot properly break down some branched fats and some bile acid building blocks. Because of that, harmful substances such as pristanic acid and unusual C27 bile acid intermediates can build up. Some people become sick in infancy with cholestasis and liver disease, while others become sick later with nerve, brain, eye, and walking problems. The disease is rare, and treatment evidence is limited, so care usually combines one core disease-directed treatment with many supportive treatments chosen for the person’s symptoms.
This disease happens because both copies of the AMACR gene do not work well. The AMACR enzyme normally helps the body handle special fats in peroxisomes and mitochondria. When the enzyme is missing or weak, the liver cannot make and process bile acids in the usual way, and the nerves and brain may also be harmed by toxic fat products. This is why a patient may have jaundice, poor fat absorption, vitamin deficiency, seizures, migraine, neuropathy, stroke-like episodes, retinal problems, or slow loss of thinking ability.
This disease is usually passed down in an autosomal recessive way. That means a person usually gets one changed AMACR gene from the mother and one changed AMACR gene from the father. A person with only one changed copy is usually a carrier and often does not have the disease. Because the disorder is very rare, it can be missed for many years, especially when symptoms look like other nerve or brain diseases.
Other Names
Alpha-methyl-acyl-CoA racemase deficiency may also be called AMACR deficiency, alpha-methylacyl-CoA racemase deficiency, 2-methylacyl-CoA racemase deficiency, or in some settings congenital bile acid synthesis defect type 4 when the liver and bile acid problem is the main feature. These names describe the same basic enzyme problem, but doctors may use one name more than another depending on whether the main problem is neurological or related to bile acids and liver function.
Types
-
Adult-onset neurologic type
-
Infant or childhood liver-predominant type
-
Mixed neurologic and liver type
-
Mild or slowly progressive type
-
Biochemical or minimally symptomatic type
The adult-onset neurologic type is the best known form. In this form, the person may develop seizures, thinking problems, migraine, nerve damage, balance trouble, retinopathy, or episodes of encephalopathy. This form often begins in adult life and may slowly progress.
The infant or childhood liver-predominant type is less common but important. In this type, the main problem can be cholestatic liver disease, fat malabsorption, enlarged liver, liver enzyme changes, or vitamin deficiency related to poor bile acid production.
Causes
The main cause of this disease is a biallelic pathogenic variant in the AMACR gene. In simple words, both copies of the gene have harmful changes, so the body cannot make enough working enzyme.
1. Homozygous AMACR mutation. This means the same harmful gene change is present in both copies of the AMACR gene. This can strongly lower enzyme function.
2. Compound heterozygous AMACR mutation. This means two different harmful changes affect the two AMACR gene copies. The result can still be enzyme deficiency.
3. Carrier parents. When both parents carry one changed copy, a child can inherit both changed copies and develop the disease.
4. Autosomal recessive inheritance. This inheritance pattern is the genetic reason the disease appears in affected families.
5. Consanguinity. When parents are related by blood, the chance of inheriting the same rare gene change from both sides can be higher.
6. Loss of enzyme activity. The AMACR enzyme may be absent or work very poorly, so fat breakdown becomes abnormal.
7. Poor breakdown of branched-chain fatty acids. The body cannot process some fatty acids correctly, and this contributes to toxic buildup.
8. Pristanic acid accumulation. High pristanic acid is one of the main biochemical problems in AMACR deficiency.
9. Abnormal pristanic-to-phytanic acid ratio. This abnormal pattern can reflect defective AMACR activity and support the disease mechanism.
10. Buildup of C27 bile acid intermediates. These abnormal bile acid substances can collect when the pathway is blocked.
11. Impaired bile acid synthesis. When bile acid production is disturbed, digestion and liver function can also be affected.
12. Peroxisomal metabolic dysfunction. AMACR works in peroxisomes, so deficiency causes a peroxisomal metabolic disorder.
13. Mitochondrial involvement. The enzyme is also present in mitochondria, so loss of function may affect cellular energy-related pathways too.
14. Toxic effect on nerves. The abnormal fat and bile intermediates may damage peripheral nerves over time.
15. Toxic effect on brain tissue. The same abnormal buildup may affect the brain and lead to seizures, encephalopathy, and white matter changes.
16. Toxic effect on retina. The eye, especially the retina, can be affected and cause visual problems or retinal dysfunction.
17. Severe pathogenic variants. Some gene changes may produce a more serious loss of enzyme function and earlier disease. This is a genotype-phenotype idea seen in rare disease reports.
18. Milder pathogenic variants. Some people may have slower disease or few symptoms for many years, even though the biochemical defect is present.
19. Liver-predominant metabolic disturbance. In some patients, the main effect of the gene defect appears first in bile acid synthesis and liver function.
20. Neurologic-predominant metabolic disturbance. In many adults, the same genetic defect mainly appears as nerve and brain disease rather than liver disease.
Symptoms
1. Cognitive decline. Some people slowly develop memory loss, poor concentration, or reduced thinking ability.
2. Seizures. Recurrent seizures are a common reported feature in adult cases.
3. Migraine or severe headaches. Some patients have migraine-like headaches as part of the disease.
4. Encephalopathy. This means episodes of brain dysfunction with confusion, altered awareness, or stroke-like symptoms.
5. Loss of consciousness during attacks. During severe brain episodes, a person may become drowsy or unresponsive.
6. Sensorimotor neuropathy. This causes weakness, numbness, tingling, or reduced feeling in the arms and legs.
7. Muscle weakness. Weakness can happen because the peripheral nerves are damaged.
8. Spasticity. Some patients develop stiffness and increased muscle tone.
9. Ataxia. This means poor balance and unsteady walking due to nervous system involvement.
10. Tremor. Shaking movements can be present in some reported patients.
11. Visual failure or blurred vision. Vision may become worse because the retina is affected.
12. Retinopathy or retinal dysfunction. Damage to the light-sensitive layer of the eye may occur, even before major visual complaints.
13. Behavioral or psychiatric change. Some case reports describe behavior change or disturbed thinking during attacks.
14. Liver-related symptoms in early cases. Some children may show jaundice, poor fat absorption, or enlarged liver when the liver form is present.
15. Fat-soluble vitamin problems. In bile acid-related cases, poor absorption can lead to vitamin deficiency problems, including vitamin K-related issues.
Diagnostic Tests
AMACR deficiency is usually diagnosed by putting together the history, physical examination, blood and urine metabolic tests, nerve and eye testing, imaging, and genetic confirmation. No single bedside sign is enough by itself. Doctors usually suspect it when a patient has unexplained neuropathy, seizures, encephalopathy, retinopathy, or unusual bile acid findings.
1. General physical examination. The doctor checks alertness, walking, muscle bulk, liver size, and general health. This does not confirm the disease, but it helps show which body systems are affected.
2. Full neurologic examination. The doctor checks memory, speech, strength, reflexes, sensation, coordination, and gait. This is important because nerve and brain problems are common in AMACR deficiency.
3. Sensory testing at the bedside. Light touch, pain, vibration, and position sense can be checked to look for neuropathy. This is a useful manual clinical test.
4. Muscle tone and spasticity assessment. The doctor moves the arms and legs to see whether there is abnormal stiffness. This helps detect upper motor pathway involvement.
5. Coordination tests. Finger-to-nose and heel-to-shin testing can help detect ataxia and cerebellar involvement.
6. Gait assessment. Watching the person walk can show imbalance, weakness, or spastic gait.
7. Ophthalmologic examination. A full eye check is important because retinal disease may be present.
8. Fundus examination. Looking at the retina can show pigmentary retinopathy or other retinal changes.
9. Visual field testing. This can help find subtle retinal or visual pathway loss. It is useful when retinopathy is suspected.
10. Electroretinography. This electrodiagnostic eye test measures retinal function and may detect disease even without obvious visual symptoms.
11. Nerve conduction studies. This electrodiagnostic test checks how well peripheral nerves carry signals and helps confirm sensorimotor neuropathy.
12. Electromyography. EMG may be added with nerve studies to better understand nerve and muscle involvement.
13. Electroencephalography. EEG can help evaluate seizures or episodes of encephalopathy.
14. Serum pristanic acid level. This is one of the most important lab tests because pristanic acid is often clearly elevated in AMACR deficiency.
15. Pristanic acid to phytanic acid ratio. This ratio may also be abnormal and support the diagnosis.
16. Plasma bile acid intermediate testing. Increased C27 bile acid intermediates strongly support AMACR deficiency, especially in bile acid-related cases.
17. Liver function tests. Blood tests such as liver enzymes can help when the disease affects the liver.
18. Fat-soluble vitamin testing. Vitamin levels may be checked in patients with cholestasis or poor fat absorption.
19. Brain MRI. Imaging may show white matter changes or lesions during neurologic attacks, and MRI has been helpful in adult cases.
20. AMACR genetic testing. Molecular testing of the AMACR gene is the key confirmatory test. Finding disease-causing variants in both gene copies confirms the diagnosis in the right clinical setting.
Non-Pharmacological Treatments
1. Rare-disease specialist follow-up. Regular care with metabolic, liver, neurology, eye, and nutrition doctors helps catch problems early. The purpose is early detection. The mechanism is simple: repeated review can find rising liver tests, worsening neuropathy, retinal changes, or nutrition failure before major damage occurs.
2. Low phytanic acid diet. This is one of the most important lifestyle treatments. The purpose is to reduce toxic fat load. The mechanism is lowering intake of foods that lead to phytanic and pristanic acid buildup, especially some ruminant fats and high-fat dairy products.
3. Low pristanic acid exposure. Food choices that reduce branched-chain fat burden may help protect the nervous system over time. The purpose is long-term neuroprotection. The mechanism is reducing the substrate that the body cannot handle well.
4. Medical nutrition therapy with a dietitian. A dietitian can help restrict harmful fats while still giving enough calories, protein, and vitamins. The purpose is safe nutrition. The mechanism is personalized meal planning that prevents malnutrition.
5. Fat-soluble vitamin monitoring. Vitamins A, D, E, and K may fall when cholestasis reduces fat absorption. The purpose is to avoid deficiency. The mechanism is regular blood testing and guided nutrition adjustment.
6. Physical therapy. This is useful for weakness, gait problems, stiffness, and deconditioning. The purpose is to preserve movement and balance. The mechanism is guided exercise, stretching, and muscle retraining.
7. Occupational therapy. This helps with dressing, writing, bathing, and daily tasks. The purpose is independence. The mechanism is adaptive techniques and home tools that make weak hands and poor balance easier to manage.
8. Speech and swallow therapy. Some patients with neurologic disease may have swallowing or speech difficulty. The purpose is safer eating and better communication. The mechanism is muscle training, swallowing strategies, and texture changes.
9. Fall-prevention training. Balance problems and neuropathy can cause falls. The purpose is injury prevention. The mechanism is gait training, cane or walker use, and home safety changes such as rails and better lighting.
10. Visual monitoring. Retinal dysfunction can be present even without symptoms. The purpose is early eye detection. The mechanism is regular ophthalmology review with retinal testing when needed.
11. Seizure safety education. Families should learn first aid, trigger avoidance, and medicine adherence. The purpose is injury reduction. The mechanism is quicker response and fewer avoidable seizure triggers.
12. Migraine trigger control. Good sleep, hydration, regular meals, and stress control can reduce migraine attacks. The purpose is lower headache burden. The mechanism is stabilizing brain and vascular triggers.
13. Liver-friendly lifestyle. Avoid alcohol and avoid unnecessary liver-toxic products. The purpose is liver protection. The mechanism is reducing extra stress on an already vulnerable liver.
14. Regular liver blood tests. Liver enzymes, bilirubin, clotting tests, and nutrition markers should be checked. The purpose is monitoring disease activity. The mechanism is early response to biochemical worsening.
15. Brain and nerve monitoring. MRI, neuro exam, and nerve testing may be needed in symptomatic patients. The purpose is tracking progression. The mechanism is showing whether treatment is stabilizing the nervous system.
16. Home exercise plan. Gentle daily activity helps endurance and stiffness. The purpose is function maintenance. The mechanism is preventing disuse weakness and preserving joint motion.
17. Nutrition support for infants or severe cases. High-calorie feeding plans, tube feeding, or special support may be needed when growth is poor. The purpose is growth and healing. The mechanism is improving intake despite cholestasis or neurologic disease.
18. Psychological and cognitive support. Some patients develop cognitive decline or emotional stress. The purpose is better quality of life. The mechanism is counseling, neuropsychology support, and family education.
19. Genetic counseling. Families should learn inheritance and testing options. The purpose is future family planning. The mechanism is explaining autosomal recessive risk and carrier testing.
20. Early treatment adherence. The 2024 and 2025 literature suggests earlier recognition and long-term follow-up matter because untreated buildup may slowly damage liver, retina, brain, and nerves. The purpose is to slow complications. The mechanism is reducing toxic metabolite exposure over years.
Drug Treatments
1. Cholic acid. This is the key disease-directed medicine. FDA-approved CHOLBAM is used for bile acid synthesis disorders. Usual dose is 10 to 15 mg/kg/day by mouth once daily or in two divided doses. Purpose: replace missing primary bile acids, improve bile flow, suppress abnormal bile acid production, and improve fat absorption. Side effects can include diarrhea and liver-related worsening in some settings, so monitoring is needed.
2. Chenodiol / chenodeoxycholic acid. This is not FDA-approved for AMACR deficiency itself, but bile acid replacement with chenodeoxycholic acid has been discussed in related bile acid disorders and case-based practice. Use is specialist-led and off-label here. Purpose: reduce abnormal bile acid synthesis. Important caution: it can injure the liver if used wrongly.
3. Ursodiol. Ursodiol is approved for primary biliary disease, not AMACR deficiency, but some clinicians may consider it for cholestatic symptoms in selected patients. It is supportive, not curative. Adult FDA dosing for its approved liver use is usually 13 to 15 mg/kg/day in divided doses.
4. Levetiracetam. Used if seizures occur. FDA label supports seizure treatment; typical adult starting dose is often 500 mg twice daily, adjusted by the treating neurologist. Purpose: seizure control. Mechanism: stabilizes abnormal neuronal firing. Common side effects include sleepiness, dizziness, and mood changes.
5. Lamotrigine. Another seizure medicine used when appropriate. It must be started slowly because of risk of serious rash. Purpose: seizure prevention. Mechanism: reduces abnormal electrical activity in the brain.
6. Topiramate. This may help seizures and migraine prevention. Purpose: reduce seizures or migraine frequency. Mechanism: dampens overactive nerve signaling. Side effects may include thinking slowing, tingling, weight loss, and kidney stone risk.
7. Divalproex sodium. This can treat seizures and migraine prevention, but it needs great caution in liver disease because FDA labeling warns about serious hepatotoxicity. It is often a poor choice if liver injury is active.
8. Pregabalin. Used for neuropathic pain in selected patients. Usual labeled starting total dose for neuropathic pain is 150 mg/day in divided doses, increased if needed. Side effects can include dizziness, sleepiness, swelling, and weight gain.
9. Gabapentin. Also used for neuropathic pain or as adjunct seizure medicine. Purpose: reduce nerve pain. Mechanism: lowers excitatory signaling in pain pathways. Side effects include dizziness and sleepiness.
10. Baclofen. Used for spasticity or painful muscle tightness. Purpose: relax muscles and improve movement. Mechanism: GABA-B agonist effect in the spinal cord. Side effects include weakness, sleepiness, and withdrawal problems if stopped suddenly.
11. Duloxetine. Used for chronic neuropathic-type pain in selected adults. Purpose: lower pain and sometimes improve mood. Mechanism: serotonin and norepinephrine reuptake inhibition. Side effects include nausea, dry mouth, and sleep changes.
12. Amitriptyline. Another option for neuropathic pain or migraine prevention at low doses. Side effects can include dry mouth, constipation, sleepiness, and heart rhythm risk in overdose.
13. Sumatriptan. Used for acute migraine attacks, not prevention. It is avoided in some vascular and stroke-risk conditions.
14. Ondansetron. Helpful for nausea and vomiting during acute illness. It does not treat the disease itself. Side effects can include constipation and QT prolongation risk.
15. Levocarnitine. FDA labeling supports use in some inborn errors with secondary carnitine deficiency. It is not a standard AMACR cure, but may be considered when deficiency is documented.
16. Vitamin A, 17. Vitamin D, 18. Vitamin E, 19. Vitamin K, and 20. Multivitamin replacement may be needed when cholestasis causes poor fat absorption. These are supportive, not curative. They help vision, bone health, antioxidant balance, clotting, and general nutrition. Dosing must be individualized by blood levels and liver team advice.
Dietary Molecular Supplements
Vitamin A, vitamin D, vitamin E, vitamin K, omega-3 fatty acids, medium-chain triglyceride nutrition support, calcium, zinc, selenium, and iron may be considered only when deficiency or need is confirmed. In AMACR deficiency, the main nutritional problem is often poor fat absorption and deficiency of fat-soluble vitamins during cholestasis. These supplements help vision, immunity, bone strength, antioxidant protection, clotting, growth, and anemia support, but they do not correct the basic enzyme defect. Dose must be chosen by a clinician because excess fat-soluble vitamins can also be harmful.
Immunity Booster, Regenerative, or Stem Cell Drugs
There are no proven FDA-approved immunity booster drugs, regenerative medicines, stem-cell drugs, or gene therapies specifically for AMACR deficiency. For this reason, these treatments are not standard care and should not be presented as established therapy. In very severe end-stage liver disease, transplantation-based care may be considered, but that is not the same as a stem-cell drug cure.
Surgeries or Procedures
Surgery is not common in AMACR deficiency, but a few procedures may be needed in severe cases. Liver transplantation may be done for liver failure. Liver biopsy may be done to understand unexplained cholestatic disease. Feeding tube placement may help severe poor intake or growth failure. Central venous access may be needed in patients requiring long nutrition support. Procedure-based management of complications, such as treatment of biliary obstruction if it occurs, may be necessary case by case. These are chosen for complications, not as a routine cure.
Prevention Tips
Early diagnosis, family screening, genetic counseling, strict follow-up, low phytanic acid eating, good treatment adherence, vitamin monitoring, seizure safety, fall prevention, and avoiding alcohol or unnecessary liver-toxic medicines can lower risk of complications. Prevention in this disease means preventing damage, not preventing the genetic condition itself after birth.
When to See a Doctor
See a doctor urgently for jaundice, vomiting, severe weakness, new seizures, confusion, stroke-like symptoms, bad headache, worsening walking, vision change, bleeding, black stool, swelling, poor feeding, or weight loss. Regular follow-up is also needed even when symptoms seem mild, because retinal, liver, and nerve problems may progress quietly.
What to Eat and What to Avoid
Eat: dietitian-guided meals, enough calories, lean protein, fruits, vegetables, whole grains, hydration, and clinician-guided vitamin support. Avoid or limit: high-fat dairy, butter, ghee, cream, large amounts of ruminant meat fat, alcohol, and unplanned supplements or herbal products that may stress the liver. The exact food plan should be individualized, but the broad goal is to reduce phytanic and pristanic acid burden while protecting growth and vitamin status.
FAQs
1. Is this disease genetic? Yes, it is autosomal recessive.
2. Can it start in adults? Yes, adult-onset neurologic disease is well described.
3. Can babies get liver disease? Yes, some infants present with cholestasis.
4. Is cholic acid important? Yes, it is the main disease-directed approved treatment for bile acid synthesis disorders.
5. Does every patient need the same treatment? No, treatment depends on symptoms and age.
6. Can it cause seizures? Yes.
7. Can it affect the eyes? Yes, retinal dysfunction can occur even without obvious symptoms.
8. Can diet help? Yes, especially restriction of phytanic and related branched fats.
9. Are stem-cell drugs proven? No.
10. Can it damage nerves? Yes, neuropathy and walking problems may occur.
11. Is liver monitoring necessary? Yes.
12. Are vitamin deficiencies common in cholestasis? Yes, especially vitamins A, D, E, and K.
13. Is there a cure? There is no simple gene cure at present, but early treatment may reduce damage.
14. Can family members be tested? Yes, genetic counseling and testing can help.
15. Is long-term follow-up needed? Yes, always.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: March 12, 2025.
